Plasma HDL cholesterol and risk of myocardial infarction: a mendelian randomisation study. by Voight, Benjamin F et al.
Supplementary appendix
This appendix formed part of the original submission and has been peer reviewed. 
We post it as supplied by the authors. 
Supplement to: Voight BF, Peloso GM, Orho-Melander M, et al. Plasma HDL cholesterol 
and risk of myocardial infarction: a mendelian randomisation study. Lancet 2012; 
published online May 17. DOI:10.1016/S0140-6736(12)60312-2.
Appendix 	  	  
	  
SNP Selection and Genotyping 
We selected the initial 25 SNPs mapped for plasma HDL-C or LDL-C concentrations using a 
genome-wide association approach.1 Each selected SNP has been associated with either HDL-C 
or LDL-C at a P<5 x 10-8.  
In case-control studies, genotypes were extracted from 16 genome-wide association 
studies (GWAS) and directly genotyped in an additional 14 studies. Array-based genotyping was 
conducted using Affymetrix 500K, Affymetrix 5.0, Affymetrix 6.0, Illumina Human Hap300, 
Illumina HumanHap370, Illumina HumanHap610 chips as previously described.2 Imputation for 
un-genotyped SNPs and quality control were conducted as previously described.2 Direct 
genotyping was attempted in 13 studies using the Sequenom iPLEX MassARRAY platform or 
the Illumina HumanCVDBeadChip Infinium II assay.3 Direct genotyping at deCODE was done 
using the Centaurus (Nanogen) platform. We only considered SNPs that exceeded stringent 
quality control criteria including genotyping call rate > 95% and Hardy-Weinberg equilibrium 
filters (P > 10-6 for SNPs from GWAS or P > 0.001 for all other SNPs). 
 In each of six prospective cohort studies, LIPG Asn396Ser was directly genotyped as 
described in Supplementary Table 2.   
 
Predicted MI Risk for LIPG Asn396Ser Based on Plasma HDL-C Difference 
We estimated a predicted risk for LIPG Asn396Ser based on the relationship of this SNP with 
plasma HDL-C and the relationship of plasma HDL-C with MI in the population. For LIPG 
Asn396Ser, we estimated the SNP-to-HDL-C parameter estimate from four prospective cohort 
studies involving >25,000 participants (Supplementary Table 3).   
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We obtained the HDL-C-to-MI parameter estimates from four prospective cohort studies. 
In the Atherosclerosis Risk in Communities Study (ARIC), Copenhagen City Heart Study 
(CCHS), Framingham Heart Study (FHS) 2nd Generation participants, and Malmo Diet and 
Cancer Study-Cardiovascular Cohort (MDCS-CC), we constructed logistic regression models to 
examine the association of incident MI status with plasma LDL-C, HDL-C, or triglycerides 
(TG), excluding subjects who had had a prevalent MI or ischemic stroke. The predictor variable 
of plasma lipid fraction was modeled in standard deviation units.  Covariates in the model 
included age and gender. As a single time point measurement of a plasma lipid fraction can 
underestimate the relationship between lipids and MI,4 we adjusted the hazard ratios for 
regression dilution bias 5 in a manner consistent with other recent studies.6 The overall effect of 
each plasma lipid fraction across the four studies was summarized using fixed-effects inverse-
variance-weighted meta-analysis (Supplementary Table 4).    
Using the SNP-to-biomarker and the biomarker-to-MI relationships as inputs, we derived 
predicted MI risk for LIPG Asn396Ser. For LIPG Asn396Ser, we first calculated the change in 
plasma HDL-C in SD units. This degree of change in plasma HDL-C was algebraically 
converted to an odds ratio for MI by multiplying the plasma HDL-C change (in SD units) by the 
beta-coefficient (representing log odds ratios) from the HDL-C-to-MI modeling described 
above.6  
 
Instrumental Variable Analysis Using LIPG Asn396Ser 
We performed instrumental variable analysis in the six prospective cohort studies listed in 
Supplementary Table 5. In four of the six studies (ARIC, CCHS, HPFS, and MDCS-CC), we 
used the qvf command, with Murphy–Topel variance, to fit the data to logistic-regression models 
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for MI using LIPG Asn396Ser as a randomized instrument.7 For two studies, an alternate two-
stage regression approach was used because of the presence of related individuals (FHS) or case-
cohort design (DCH). For these two studies, in the first stage, generalized estimating equations 
(FHS) or a generalized linear model (DCH) was fitted with the outcome variable of plasma 
HDL-C and predictor variables of LIPG Asn396Ser genotype, age, and gender. In the second 
stage, a generalized linear model was used to test the association of MI status with the fitted 
HDL-C from the first stage. A summary instrumental variable estimate for the association of 
plasma HDL-C with MI risk across the six studies was generated with fixed-effects variance-
weighted meta-analysis. 
 
Mendelian randomization using multiple genetic variants as instrumental 
variables 
It has recently been proposed that statistical power for instrumental variable analysis could be 
increased if multiple genetic variants in combination were used as instruments.8 From our 
recently published genome-wide association study of plasma lipids traits involving >100,000 
individuals,9 we observed that 13 SNPs had statistical evidence at genome-wide levels of 
significance (P < 5 x 10-8) for plasma LDL-C and no evidence for association with triglycerides 
(P>0.01) or HDL-C (P>0.01). We constructed a “LDL-C genetic score” combining the LDL-C 
raising alleles at each of these 13 SNPs (Supplementary Table 9). We also observed that 14 
SNPs had statistical evidence at genome-wide levels of significance (P < 5 x 10-8) for plasma 
HDL-C and no evidence for association with triglycerides (P>0.01) or LDL-C (P>0.01). We 
constructed a “HDL-C genetic score” combining the HDL-C raising alleles at each of these 14 
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SNPs (Supplementary Table 10). Each SNP was given a weight based on the degree of LDL-C 
change or HDL-C change as estimated in ~100,000 individuals.9   
We defined genetic risk scores in the following way10: Using a set of m SNPs, for the i-th 
SNP in the j-th individual denote xij as the 0/1/2 coded genotype (for directly genotyped SNPs) 
or expected allele dosage (which takes real values between 0.0 and 2.0 for imputed SNPs). Using 
results from Teslovich et al.,9 define the set of regression coefficients to be w1, w2, ..., wm. Then 
the risk score for subject j is defined to be 
(1) sj = s0 + w1 x1j + w2 x2j + ... + wm xmj, 
where s0 is the intercept. In all our analyses, we specify the coefficients w1, w2, ..., wm to be the 
effect sizes, in standard deviation units per coded allele, estimated in single SNP analyses of 
LDL-C or HDL-C.  
We also note that, when considering multiple SNPs that are in linkage equilibrium with 
each other, and small effect sizes per SNP, effect sizes estimated jointly for all SNPs using a 
multiple regression model are effectively identical to those estimated in a series of single SNP 
regression models. Thus regression on the risk score can be reconstructed from regressions on 
each of the m SNPs in turn, without further access to individual-level data. 
The calculations involved are of the same type as for meta-analysis; the coefficient of the 
risk score is a weighted mean of the per-SNP regression coefficients, where each is weighted by 
its corresponding wi. The estimated variance of the risk score is given by similarly weighting the 
estimated variances (squared standard errors) of each per-SNP regression coefficient. The 
assumption of zero LD between SNPs ensures that these contributions are independent. 
Importantly, as with inverse-variance weighted meta-analysis, in large samples this procedure 
gives valid p-values under the null, i.e. when there is no relationship between the “lookup” 
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phenotype and any variants at the SNPs contributing to the risk score. 
Using SNP-specific results in this way, we estimated and tested the coefficient of the risk 
score in independent “lookup” results using logistic regression for myocardial infarction 
phenotype from the published Coronary ARtery DIsease Genome-wide Replication And Meta-
analysis (CARDIoGRAM) consortium GWAS study.11,12  These estimates and tests inherit the 
covariate adjustment performed in the original SNP-specific analysis. 
 The CARDIoGRAM consortium combines data from 14 GWAS in individuals with 
European ancestry including 22,233 cases with coronary artery disease and/or MI and 64,762 
controls.11  For all of the participating studies, genome-wide scans were performed in the years 
2006-2009 using either Affymetrix or Illumina platforms followed by imputation of genotypes in 
most studies. Statistical methods have been standardized across the studies, and an analysis 
platform has been created to allow summarized analyses on coronary artery disease, MI, and 
related phenotypes.  We restricted our analysis to the subgroup of up to 12,482 MI cases and 
41,331 MI-free controls.   
 
Descriptions of Case-Control Studies 
 
Italian ATVB Study, Heart Attack Risk in Puget Sound, REGICOR, MGH Premature 
Coronary Artery Disease Study, FINRISK, Malmo Diet and Cancer Study Early-Onset MI, 
PennCATH, deCODE, MedSTAR, Verona Heart Study, Mid-America Heart Institute, 
Irish Family Study, INTERHEART, and AMI Gene Study/Dortmund Health Study:  
Details for the recruitment of participants for these studies have been described in detail in a 
recent publication.2 
 
WTCCC MI and German MI Family Study I:  Details for the recruitment of the WTCCC 
CAD and German MI Family Study I are as recently described.13 For the present report, we 
limited the analysis to cases that met clinical criterion for MI. 
 
SHEEP:  Details for the recruitment of SHEEP subjects are as recently described.14,15 
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Malmo Diet and Cancer Study Later-Onset MI:  The Malmö Diet and Cancer (MDCS) study 
is a community-based prospective epidemiologic cohort of 28,449 persons recruited for a 
baseline examination between 1991 and 1996.16 All participants underwent a medical history, a 
physical examination, and a laboratory assessment for cardiovascular risk factors as described 
previously.17 From this cohort, 1,059 persons with MI at older age (age at MI for men >50 or 
women >60) were studied. Fatal or non-fatal MI status was determined as described previously.18 
For each case, a random control was selected.  
   
COROGENE:  Initially a sample was collected including all consecutive Finnish patients 
assigned to coronary angiogram within a 20-month period (June 2006–March 2008, n=5,330) in 
the Helsinki University Central Hospital. Data collection included a questionnaire, information 
on previous medical conditions and cardiovascular risk factors, hospital records for patients’ 
history, various laboratory measurements, ECG, echocardiography, and medication. 
Approximately 22% of the patients were angiographically free of coronary artery disease (CAD). 
Different stages of atherosclerosis were found in 75% of patients, of which 53% had acute 
coronary syndrome (ACS; n=2,172). These ACS patients were selected as the complete set of 
COROGENE cases. 
 The controls for COROGENE cases were selected from the FINRISK 1997, 2002 and 
2007, participants from the Helsinki-Vantaa region using risk set sampling.19 For each case 
independently (= with replacement), two controls (if possible) were sampled from all controls 
who fulfilled the following criteria. The controls had to be 1) of the same sex, 2) of the same 
birth cohort (within ±5 years) to reduce the effect of secular trends and 3) free of cardiovascular 
disease (CVD) at least until the case’s age of having ACS.  
 
The CADomics Study:  CADomics (Coronary Artery Disease and genomics) is a German-
based case-control study of CAD. It is a pooled study from the population-based Gutenberg-
Heart Study (GHS) and the hospital (cath-lab)-based Atherogene Registry.20-22 
The GHS is a population-based, prospective, observational single-center cohort study in 
the Rhein-Main-Region in western mid-Germany. The primary aim of GHS is to evaluate and 
improve cardiovascular risk stratification. The sample was drawn randomly from the 
governmental local registry offices that contain all citizens in the city of Mainz and the district of 
Mainz-Bingen. Individuals between ages 35 and 74 were enrolled and enrollment was stratified 
for gender, residence (urban and rural) and decade of age. Exclusion criteria were insufficient 
knowledge of the German language, and physical or psychological inability to participate. 
Cardiovascular risk factors were assessed by a computer-assisted personal interview, from 
laboratory analyses of a venous blood sample in a fasting state, blood pressure and 
anthropometric measurements.  
The Atherogene Registry has been described elsewhere.20 Briefly, between June 1999 
and February 2004, patients with documented CAD referred to the Department of Medicine II of 
the Johannes Gutenberg-University in Mainz, Germany and the Department of Medicine of the 
German Federal Armed Forces Central Hospital, Koblenz, were enrolled in the AtheroGene 
study registry. All participants had coronary angiography. Information on cardiovascular risk 
factors and coronary angiography were extracted from medical records. The angiograms were 
scored at the time of procedure by an interventional cardiologist.   
For the current analysis, 1,212 had a diagnosis of MI and were included as cases in this 
report. A total of 2,952 did not have a history of MI and were included as controls.  
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Ottawa Heart Genomics Study I and I:  Details for the recruitment of subjects are as recently 
described.23,24 
 
GRACE GENETICS:  The GRACE Genetics study prospectively enrolled 683 patients with an 
ACS between January 2001 and December 2007 in two hospitals in Belgium (University 
Hospital Gasthuisberg, Leuven and Onze-Lieve-Vrouw Clinic, Aalst). To ensure enrollment of 
an unselected ACS population, sites recruited the first 10-20 consecutive eligible patients each 
month.25 Controls comprised 656 healthy blood donors from the Red Cross Belgium recruited 
from January to March 2008.26  
 
PROCARDIS:  The PROCARDIS study is a multi-centre case-control study in which CAD 
cases and controls were recruited from four European countries (United Kingdom, Italy, 
Sweden and Germany) according to pre-specified criteria.27 All participants provided written 
informed consent to a protocol that was approved by the Ethics Committees of the participating 
institutions. All cases had a diagnosis of CAD before age 66 years and also had a sibling with 
CAD before age 66 years. Among the 3146 CAD cases, 2183 had a diagnosis of MI (91% 
confirmed by hospital discharge or general practice records) and were included as cases in this 
report. Controls with no personal or sibling history of CAD before age 66 years were 
contemporaneously recruited using the same infrastructure. 
 
Utrecht Cardiovascular Pharmacogenetics (UCP) Studies:  Participants were enrolled from 
the population-based Pharmaco-Morbidity Record Linkage System (PHARMO, 
www.pharmo.nl). PHARMO links drug dispensing histories from a representative sample of 
Dutch community pharmacies to the national registration of hospital discharges (Landelijke 
Medische Registratie, LMR) since 1985 on a continuous basis. Currently, the base population of 
PHARMO covers approximately 2,000,000 community-dwelling inhabitants of several 
population-defined areas in the Netherlands. Approval for this study was obtained from the 
Medical Ethics Committee of the University Medical Center Utrecht, The Netherlands. 
Briefly, patients with a high cardiovascular risk defined as those who received a 
prescription for an antihypertensive drug, or a glucose lowering drug, or who had 
hypercholesterolemia (prescription for a cholesterol-lowering drug or total cholesterol > 5.0 
mmol/l), were selected from the PHARMO database. From this cohort, patients hospitalized for 
acute coronary syndrome (ACS) were included as cases (acute myocardial infarction (AMI, 
International Classification of Diseases (ICD)-9 code 410)) or (sub)acute forms of ischemic heart 
disease (ICD-9 codes 411.1 and 411.8)) if they were registered in PHARMO for at least one year 
and were older than 18 years. The index date was defined as the date of hospitalization for the 
first ACS. Controls met the same eligibility criteria as the cases, but had not developed ACS.  
Participants were recruited through community pharmacies, where they received a letter 
in which the purpose of the study was explained. They were asked to return an informed consent 
form and a filled-out questionnaire. After the participant had consented to participate in the 
study, (s)he was sent an Oragene collection kit (hypercholesterolemic and diabetic cohort), or 
three cotton swabs and tubes containing buffer (hypertensive cohort) to collect saliva. All 
participants were explicitly asked to consent for the collection, storage and genotyping of the 
DNA material. 
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EPIC-NL:  The EPIC-NL cohort is the Dutch contribution to the European Prospective 
Investigation into Cancer and Nutrition, and consists of the Prospect cohort, a prospective 
population based cohort of 17,357 women between 49-70 years at recruitment participating in 
breast cancer screening between 1993 and 1997, and the Monitoring Project on Risk Factors for 
Chronic Diseases (MORGEN) cohort, consisting of 22,654 men and women between 20-59 
years at recruitment in three Dutch towns (Amsterdam, Maastricht and Doetinchem). At 
baseline, a general questionnaire containing questions on demographic characteristics, smoking, 
presence of chronic diseases and other potential risk factors was filled out by all participants. 
Body weight, height, waist, and hip circumference were also measured, and a n on-fasting blood 
sample was taken. Information on incident coronary heart disease occurrence during follow-up 
was obtained through linkage with the database of hospital discharge diagnoses from the Dutch 
National Medical Registry. For this study, 334 MI cases and 1,827 randomly-selected MI-free 
controls were genotyped. 
 
AngioGOKARD/KORA:  The Lübeck and Regensburg angiographic study (Angio/GOKARD) 
includes 1,953 patients with angiographically proven CAD who underwent cardiac 
catheterization at the University Hospital Schleswig-Holstein, Campus Lübeck and University 
Hospital Regensburg between 2005 and 2010. Patients were not selected for particular risk 
factors or phenotypes.28 Controls comprise individuals from the population-based 
MONICA/KORA Augsburg survey F3 (n=1,564).29 
 
PopGen:  The PopGen CAD sample (n=2,433) comprised unrelated German MI patients with 
early onset of disease who were recruited in Schleswig-Holstein, through regional catheterisation 
laboratories in the northernmost region in Germany (University Hospital Schleswig-Holstein, 
Campus Kiel, local hospitals Rendsburg, Schleswig, Flensburg, Heide), that have been contacted 
by the population-based PopGen biobank (www.PopGen.de). 1,687 PopGen-controls of the 
Max-Rubner-Institute were part of the Metabolic Intervention Cohort Kiel (MICK) and selected 
by age from the general population via the registration register of the same region.30 
 
PROMIS: Details for the recruitment of the PROMIS subjects are as recently described.31 
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Descriptions of Cohort Studies 
 
Atherosclerosis Risk in Communities Study (ARIC):  The ARIC study is a prospective 
population-based study in 15,792 men and women, including 11,478 non-Hispanic whites and 
4,314 African-Americans, drawn from 4 U.S. communities (suburban Minneapolis, Minnesota; 
Washington County, Maryland; Forsyth County, North Carolina, and Jackson, Mississippi). The 
baseline examination for this report extended from 1987 – 1989 and for this study, we included 
only non-Hispanic whites and excluded those with prevalent CVD. Among the remaining 
individuals, we analyzed the association of LIPG Asn396Ser genotype with incident fatal or non-
fatal MI. The follow-up data in this study include events up to January 1, 2003. The incidence of 
MI was determined by contacting participants annually, by identifying hospitalizations and 
deaths during the previous year, and by surveying discharge lists from local hospitals and death 
certificates from state vital-statistics offices for potential cardiovascular events. The incidence of 
MI and plasma lipid measurements was determined as previously described.32  
 
Copenhagen City Heart Study (CCHS):  The Copenhagen City Heart Study is a prospective 
study of a cohort of >10,000 persons randomly selected from the population of the city of 
Copenhagen.6 The baseline examination for this report extended from 1991-1994 and we 
excluded all individuals all individuals with prevalent CVD at the baseline exam. Among the 
remaining individuals, we analyzed the association of LIPG Asn396Ser genotype with incident 
fatal or non-fatal MI. The follow-up data in this study include events up to January 1, 2009. The 
incidence of MI and plasma lipid measurements was determined as previously described.6 
 
Danish Diet, Cancer, and Health Study (DCH):  The Diet, Cancer and Health (DCH) study 
was initiated in 1993 when a total of 160,725 inhabitants of the greater Copenhagen or Aarhus 
areas who were born in Denmark and aged 50 to 64 years, were invited to participate. Eligible 
participants were without a record of cancer in the Danish Cancer Registry at the time of 
invitation. In total, 27,178 men and 29,875 women participated. Participants received a detailed 
FFQ by mail prior to the visit to the study clinic, where they also filled in a lifestyle 
questionnaire, and were asked to provide a blood sample. A detailed description of the cohort has 
been published previously.33 A case-cohort study was designed using incident acute coronary 
syndrome (ACS), including unstable angina pectoris, MI, and sudden cardiac death as the 
outcome. 
Information on the disease endpoint was obtained by linkage with central Danish 
registries via the unique identification number assigned to all Danish citizens. Hospital records of 
potential cases were retrieved from hospitals for participants who were registered with a first-
time discharge diagnosis of ACS (ICD-8 codes 410-410.99, 427.27 and ICD-10 codes I20.0, 
I21.x, I46.x) in The Danish National Register of Patients, which covers all hospital discharge 
diagnoses since 1977 and from 1995 all discharge diagnosis from out-patient clinics (until Jan 1, 
2004). Cases were classified by three reviewers according to symptoms, signs, coronary 
biomarkers, ECGs and/or autopsy findings in accordance with the current recommendations of 
the American Heart Association and the European Society of Cardiology (AHA/ECS).34 Further, 
linkage to the Cause of Death Register allowed for identification of participants with ACS coded 
as a primary or secondary cause of death (to Jan 1, 2004). In total, for this report, 933 cases of 
MI were identified, however some of these were later excluded because of lacking questionnaire 
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data. For the creation of the cohort sample, 1588 participants were selected from the entire DCH 
study at random. 
 
Framingham Heart Study (FHS):  Design and recruitment strategies for the Offspring cohort 
of the Framingham Heart Study have been described elsewhere.35 Since the initiation of the 
study in 1971, participants are seen in the FHS clinic every 4 to 8 years on average. Participants 
included in the current study (n=1,512) are from a subset of unrelated individuals from the 
Framingham offspring cohort who provided blood samples for DNA extraction at the sixth 
examination cycle. All participants underwent continuous surveillance for incident CVD events 
and death. A team of 3 physicians reviews all available information, hospitalization records and 
physician charts to adjudicate outcome events.36 We excluded all individuals with prevalent 
CVD at the sixth examination cycle. Follow-up for incident MI or fatal CHD (n=52) extended 
from the sixth examination cycle (considered baseline for this study) until December 31, 2007.  
 
Health Professionals Follow-up Study (HPFS):  The HPFS was initiated in 1986 when 51,529 
male health professionals between 40 and 75 years of age completed a food frequency 
questionnaire (FFQ) and a medical history questionnaire. The participants have been followed 
with repeated questionnaires on lifestyle and health every 2 years and FFQ's every 4 years.  
Blood samples were requested between 1993 and 1996 and obtained from 18,225 participants.37 
For a nested case-control study, 426 incident nonfatal MI or fatal CHD cases that 
occurred between blood draw and January 31, 2004 were collected and ascertained. Cases of MI 
and fatal CHD were identified primarily through review of medical records.  Participants who 
had reported an incident CHD on the follow-up questionnaire were contacted for confirmation 
and permission to review medical records was requested. Medical records for deceased 
participants were also sought for deaths that were identified by families and postal officials and 
through the National Death Index. Physicians blinded to the participant’s questionnaire reports 
reviewed all medical records.  
 
Malmo-Diet and Cancer Study (MDC):  MDC is a community-based prospective 
epidemiologic cohort of 28,449 persons recruited for a baseline examination between 1991 and 
1996.38 All participants underwent a medical history, a physical examination, and a laboratory 
assessment for cardiovascular risk factors.  The final data with LIPG Asn396Ser genotype was 
available from 27,041 subjects. All participants gave written informed consent. 
Cardiovascular events were ascertained through linkage of the 10-digit personal 
identification number of each Swedish citizen with three registries: the Swedish Hospital 
Discharge Register, the Swedish Cause of Death Register, and the Stroke Register of Malmö. 
The prespecified composite end point was defined as MI infarction and death from CHD. MI was 
defined on the basis of codes 410 and I21 in the International Classification of Diseases, 9th 
Revision and 10th Revision (ICD-9 and ICD-10), respectively. Death from CHD was defined on 
the basis of codes 412 and 414 (ICD-9) or I22–I23 and I25 (ICD-10) in the Swedish Cause of 
Death Register. Follow-up extended to December 31, 2003.    
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Supplementary Table 1.  Characteristics of Cases with Myocardial Infarction and Controls Free of Myocardial Infarction* 
 
Study Italian ATVB Study Heart Attack Risk in Puget Sound REGICOR 
MGH Premature Coronary 
Artery Disease Study FINRISK 
Malmö Diet and 
Cancer Study  
Early-Onset MI 
 cases Controls cases controls cases controls cases controls Cases controls cases controls 
N  1,693 1,668 505 559 312 317 204 260 167 172 86 99 
MI age criterion men or women ≤ 45 -- 
men ≤50 or 
women ≤ 60 -- 
men ≤50 or 
women ≤ 60 -- 
men ≤50 or 
women ≤ 60 -- 
men ≤50 or 
women ≤ 60 -- 
men ≤50 or 
women ≤ 60 -- 
Genotyping platform Affymetrix 6.0 
Affymetrix 
6.0 
Affymetrix 
6.0 
Affymetrix  
6.0 
Affymetrix 
6.0 
Affymetrix 
6.0 
Affymetrix 
6.0 
Affymetrix 
6.0 
Affymetrix 
6.0 
Affymetrix 
6.0 
Affymetrix  
6.0 
Affymetrix 
6.0 
Country of origin Italy Italy U.S. U.S. Spain Spain U.S. U.S. Finland Finland Sweden Sweden 
Mean age (y) † 39.4 ± 4.9 39.3 ± 5.0 46.0 ± 6.9 45.2 ± 7.3 45.9 ± 5.8 46.0 ± 5.6 47.0 ± 6.1 53.8 ± 11.1 47.1 ± 6.2 47.1 ± 6.0 48.5 ± 4.4 48.7 ± 4.6 
Female gender (%) 11.4 11.6 51.1 55.5 20.2 21.5 29.9 33.5 33.5 31.4 41.9 42.4 
Study WTCCC MI German MI  Family Study I 
German MI  
Family Study II PennCATH deCODE MedSTAR 
 cases controls cases controls cases controls cases controls Cases controls cases controls 
N  1,561 2,938 875 1,644 1,222 1,874 415 468 729 29,218 420 447 
MI age criterion <66 years -- men ≤60 or 
women ≤ 65 
-- men ≤60 or 
women ≤ 65 
-- <66 years -- men<50 or women <60 -- <66 years -- 
Genotyping platform Affymetrix 500K 
Affymetrix 
500K 
Affymetrix 
500K 
Affymetrix 
500K 
Affymetrix 
6.0 
Affymetrix 
6.0 
Affymetrix 
6.0 
Affymetrix 
6.0 
Illumina 
300/370K 
Illumina 
300/370K 
Affymetrix  
6.0 
Affymetrix 
6.0 
Country of origin U.K. U.K. Germany Germany Germany Germany U.S. U.S. Iceland Iceland U.S. U.S. 
Mean age (y) † 49.3±7.9 44.7±9.3 50.2±7.9 62.5±10.1 51.3 ± 7.6 51.2±11.9 50.2±7.5 61.7 ± 9.6 56.7 ± 10.6 48.9 ± 21.6 46.8±6.8 59.7 ± 8.9 
Female gender (%) 20.2 49.2 32.5 50.5 20.3 47.9 17.6 51.7 40.8 61.3 23.8 48.8 
Study Verona Heart Study Mid-America Heart Institute Irish Family Study INTERHEART European Ancestry 
AMI Gene Study / 
Dortmund Health Study SHEEP 
 cases controls cases controls cases controls cases controls Cases controls cases controls 
N  510 388 811 650 577 719 1,886 2,231 809 1,132 1,155 1,502 
MI age criterion men ≤65 or 
women ≤ 65 
-- no age criterion -- 
men ≤55 or 
women ≤ 65 
-- no age  criterion -- men <65 -- 
men and 
women 46-70 -- 
Genotyping platform Sequenom Sequenom Sequenom Sequenom Sequenom Sequenom Sequenom Sequenom Sequenom Sequenom Sequenom Sequenom 
Country of origin Italy Italy U.S. U.S.  Northern Ireland 
Northern 
Ireland 
U.S. and 
multiple in 
Europe 
U.S. and 
multiple in 
Europe 
Germany Germany Sweden Sweden 
Mean age (y) † 57.0±9.1 58.9±12.1 61.5±12.7 60.7±12.4 45.9±6.7 55.7±8.0 61.2±12.1 60.5±12.0 52.2±8.2 52.6±13.7 59.2±7.2 59.8±7.1 
Female gender (%) 10.6 34.8 32.1 39.0 20.1 55.2 28.9 31.3 0 53.1 29.4 32.2 
Study 
Malmö Diet and  
Cancer Study Later-
Onset MI 
COROGENE CADomics Ottawa Heart Genomics Study I 
Ottawa Heart Genomics 
Study II GRACE Genetics 
 cases controls cases controls cases controls cases controls Cases controls cases controls 
N  1,059 1,056 2,172 1,579 1,212 2,952 950 1,455 1,090 933 683 656 
MI age criterion Men >50 or women >60 -- 
no age 
criterion  
no age 
criterion -- 
men ≤55 or 
women ≤ 65 
--- men ≤55 or 
women ≤ 65 
--- no age criterion  
Genotyping platform Sequenom Sequenom Illumina Illumina Affymetrix 6.0 
Affymetrix 
6.0 
Affymetrix 
500K&6.0 
Affymetrix 
500K&6.0 
Affymetrix 
6.0 
Affymetrix 
6.0 Sequenom Sequenom 
Country of origin Sweden Sweden Finland Finland Germany Germany Canada Canada Canada / U.S 
Canada / 
U.S Belgium Belgium 
Mean age (y) † 63.7 ± 5.9 63.7 ± 5.9  66.1 ± 12.0 55.7 ± 12.2  59.3 ± 10.8 55.3 ± 10.8 47.7±7.3 75.0±5.0 47.8±7.1 74.3±5.8 65.2±11.8 41.0±13.2 
18
Female gender (%) 21.4 42.6 30.8 45.5 20.5 50.5 20.8 48.0 20.9 50.3 24.4 43.3 
 
Study PROCARDIS UCP EPIC-NL AngioGOCARD/KORA PopGen PROMIS 
 cases controls cases controls cases controls cases controls Cases controls cases controls 
N  2,183 3,347 830 1,139 334 1,827 1,953 1,482 2,433 1,687 1854 1897 
MI age criterion <66 years <66 years None None None None 30-65 35-84 34-88 20-68 None None 
Genotyping platform Illumina CVD chip 
Illumina 
CVD chip 
Illumina 
CVD chip 
Illumina CVD 
chip 
Illumina 
CVD chip 
Illumina 
CVD chip Sequenom Sequenom Sequenom Sequenom 
Illumina CVD 
chip 
Illumina 
CVD chip 
Country of origin Europe Europe Netherlands Netherlands Netherlands Netherlands Germany Germany Germany Germany Pakistan Pakistan 
Mean age (y) † 52.9  ± 7.7 59.4 ± 9.9 63.7 ± 10.3 62.7 ± 10.7 54.9 ± 9.2 49.0 ± 12.1 55.1 ± 6.9 52.2 ± 13.3 61.2 ± 8.2 51.2 ± 14.4 54.5 ± 10.9 52.1 ± 10.3 
Female gender (%) 25.3 50.9 26.4 32.5 58.8 72.2 19.1 52.1 18.9 0.0 16.0 19.0 
Values with ‘±’ are means ± s.d.  
*Summary characteristics are provided for maximal number of available subjects.  For any given genotype, a subset may have been studied. 
 †Mean age at MI for cases and age at recruitment for controls. 
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Supplementary Table 2. Characteristics of Participants from Prospective Cohort Studies by Myocardial Infarction Status 
Prospective 
cohort ARIC CCHS DCH FHS HPFS MDCS
* 
MI status No event MI No event MI No event MI No event MI No event MI No event MI 
No. of 
individuals (%) 
8,214 
(93%) 
558 
(7%) 
8,964 
(93%) 
655 
(7%) 
1,588 
(63%) 
933 
(37%) 
1,462  
(97%) 
50 
(3%) 
869 
(67%) 
426 
(33%) 
25,438 
(94%) 
1,606 
(6%) 
Women, % 56 38 58 45 38 62 53 42 0 0 63 35 
Age, years 54 ± 0.1 56 ± 0.2 55 ± 0.2 66 ± 0.4 56 ± 0.1 58 ± 0.1 58 ± 0.2 63 ± 1.2 64 ± 0.3 64 ± 0.4 58 ± 0.1 62 ± 0.2 
Total 
cholesterol, 
mmol/L 
5.5 ± 0.01 5.8 ± 0.04 6.0 ± 0.01 6.6 ± 0.05 6.0 ± 0.03 6.4 ± 0.04 5.4 ± 0.03 5.6 ± 0.15 5.3 ± 0.03 5.5 ± 0.05 6.2 ± 0.02 6.3 ± 0.06  
LDL-C, 
mmol/L 3.5 ± 0.01 3.9 ± 0.04 3.6 ± 0.01 4.2 ± 0.05 3.6 ± 0.02 3.9 ± 0.04 3.3 ± 0.02 3.5 ± 0.13 3.3 ± 0.03 3.5 ± 0.04 4.2 ± 0.01 4.4 ± 0.06 
HDL-C, 
mmol/L 1.3 ± 0.01 1.1 ± 0.01 1.6 ± 0.01 1.4 ± 0.02 1.6 ± 0.01 1.4 ± 0.01 1.3 ± 0.01 1.1 ± 0.04 1.9 ± 0.01 1.1 ± 0.01 1.4  ± 0.01 1.2 ± 0.02 
TG,  
mmol/L 1.5 ± 0.01 1.9 ± 0.06 1.8 ± 0.01 2.2 ± 0.06 1.8 ± 0.03 2.3 ± 0.04 1.7 ± 0.03 2.1 ± 0.22 1.6 ± 0.04 1.9 ± 0.05  1.4 ± 0.01 1.6 ± 0.06 
Body mass 
index, kg/m2 27 ± 0.05 28 ± 0.2 25 ±0.05 27 ± 0.2 26 ± 0.13 27 ± 0.13 28 ± 0.13 28 ± 0.75 26 ± 0.1 26 ± 0.2 26 ± 0.03 27 ± 0.1 
Genotyping 
method for 
LIPG 
Asn396Ser 
Illumina CVD Chip Taqman Taqman Taqman Taqman Taqman 
ARIC, Atherosclerosis Risk in Communities Study; CCHS, Copenhagen City Heart Study; DCH, Danish Diet, Cancer, and Health Study; FHS, Framingham Heart Study; HPFS, 
Health Professionals Follow-up Study; MDCS, Malmö Diet and Cancer Study 
All continuous traits are given as means ± SEM. All categorical variables are shown in percentages.  
*Lipid traits were available for 5,042-5,173 MDCS study participants. 
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Supplementary Table 3.  Association of LIPG Asn396Ser with Plasma High-Density Lipoprotein Cholesterol in  
Four Prospective Cohort Studies  
 
 ARIC CCHS FHS MDCS-CC Meta-analysis across 4 studies 
N total 8,735 9,618 1,589 5,127 25,069 
Number of 
396Ser 
mutation 
carriers 
225 232 43 133 633 
Beta* 0.33 0.15 0.49 0.39 0.29 
SE 0.07 0.07 0.16 0.09 0.04 
P 7 x 10-7 0.02 0.002 1 x 10-5 8 x 10-13 
ARIC, Atherosclerosis Risk in Communities Study; CCHS, Copenhagen City Heart Study; FHS, Framingham Heart Study; MDCS-CC, 
Malmö Diet and Cancer Study-Cardiovascular Cohort 
In each study, association results are from a linear regression model with a predictor variable of the LIPG 396Ser allele.  The outcome 
variable was plasma high-density lipoprotein cholesterol residual after adjustment for age and gender and standardized to a mean of 0 
and SD of 1. 
*Beta represents increment change in standard deviation units for each copy of the LIPG 396Ser allele. 
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Supplementary Table 4.  Association of Plasma Lipid Level and Incident Myocardial 
Infarction in Four Prospective Cohort Studies 
 
Predictor Covariate OR per 
SD increase in  
plasma lipid level 
95% CI 
 
Atherosclerosis Risk in Communities Study 
LDL cholesterol Age, gender, HDL-C, TG 1.65 1.48 - 1.85 
HDL cholesterol Age, gender, LDL-C, TG 0.56 0.51 – 0.62 
Triglycerides Age, gender, HDL-C, LDL-C 1.40 1.20 - 1.62 
 
Copenhagen City Heart Study 
LDL cholesterol Age, gender, HDL-C, TG 1.61 1.40 - 1.85 
HDL cholesterol Age, gender, LDL-C, TG 0.74 0.64 – 0.85 
Triglycerides Age, gender, HDL-C, LDL-C 1.31 1.11 - 1.55 
 
Framingham Heart Study 
LDL cholesterol Age, gender, HDL-C, TG 1.64 1.48 - 1.82 
HDL cholesterol Age, gender, LDL-C, TG 0.71 0.61 – 0.82 
Triglycerides Age, gender, HDL-C, LDL-C 1.88 1.65 – 2.13 
 
Malmo Diet and Cancer Study – Cardiovascular Cohort 
LDL cholesterol Age, gender, HDL-C, TG 1.23 1.11 - 1.35 
HDL cholesterol Age, gender, LDL-C, TG 0.55 0.46 – 0.66 
Triglycerides Age, gender, HDL-C, LDL-C 1.01 0.86 - 1.18 
 
Meta-analysis of Four Cohort Studies 
LDL cholesterol Age, gender, HDL-C, TG 1.54 1.45 - 1.63 
HDL cholesterol Age, gender, LDL-C, TG 0.62 0.58 – 0.66 
Triglycerides Age, gender, HDL-C, LDL-C 1.42 1.31 - 1.52 
The four prospective cohort studies were:  1) ARIC, Atherosclerosis Risk in Communities Study; 2) CCHS, 
Copenhagen City Heart Study; 3) FHS, Framingham Heart Study; and 4) MDCS-CC, Malmö Diet and Cancer Study-
Cardiovascular Cohort. 
In each study for each trait, the odds ratio estimates were adjusted for regression dilution bias using a parametric 
approach.  The test-retest correlations for LDL-C, HDL-C, and TG were the following:  ARIC (0.55, 0.72, and 0.56); 
CCHS (0.60, 0.73, and 0.58); and Framingham Heart Study (0.72, 0.72, and 0.56).   
22
 
 
 
 
Supplementary Table 5. Characteristics of Participants from Prospective Cohort Studies by LIPG 396Ser Carrier Status 
Prospective 
cohort ARIC CCHS DCH FHS HPFS MDCS-CC 
LIPG 396Ser 
carrier status No Yes No Yes No Yes No Yes No Yes No Yes 
No. of 
individuals (%) 
8,510 
(97.4) 
225 
(2.6) 
9,387 
(97.6) 
232 
(2.4) 
2,458 
(97.5) 
63  
(2.5) 
6128 
(97.4) 
161 
(2.6) 
1255  
(98.2) 
23  
(1.8) 
5568 
(97.4) 
148 
(2.6) 
Women, % 55 55 57 53 38 37 55 56 0 0 58 58 
Age, years 54.2 ± 0.1 54.3 ± 0.4 55.4 ± 0.2 58.0 ± 1.0 57.1 ± 0.1 56.2 ± 0.5 46.9 ± 0.2 47.6 ± 1.0 64.2 ± 0.2 64.0 ± 1.9  57.4 ± 0.1 57.8 ± 0.5 
Total 
cholesterol, 
mmol/L 
5.54  ± 0.01 5.76  ± 0.07 6.02 ± 0.01 6.27 ± 0.08 6.15 ± 0.02 6.11 ± 0.13 5.13 ± 0.01 5.41 ± 0.08 5.32 ± 0.03 5.32 ± 0.18 6.17 ± 0.02 6.39 ± 0.10 
LDL-C, 
mmol/L 3.54 ± 0.01 3.62 ± 0.06 3.67 ± 0.01 3.74 ± 0.07 3.71 ± 0.02 3.59 ± 0.12 2.92 ± 0.01 3.04 ± 0.10 3.34 ± 0.02 3.41 ± 0.14 4.17 ± 0.01 4.22 ± 0.09 
HDL-C, 
mmol/L 1.32 ± 0.01 1.46  ± 0.03 1.57 ± 0.01 1.65 ± 0.04 1.54 ± 0.01 1.58 ± 0.05 1.38 ± 0.01 1.52 ± 0.04 1.16 ± 0.01 1.19 ± 0.09 1.38 ± 0.005 1.52 ± 0.04 
TG,  
mmol/L 1.53 ± 0.01  1.51 ± 0.06 1.79 ± 0.01 1.93 ± 0.08 1.98 ± 0.02 2.06 ± 0.13 3.41 ± 0.03 3.38 ± 0.20 1.70 ± 0.03 1.60 ± 0.19 1.37 ± 0.01 1.37 ± 0.06 
Body mass 
index, kg/m2 27.29 ± 0.33 26.95 ± 0.05 25 ± 0.04 26 ± 0.3 27 ± 0.1 26 ± 0.5 27 ± 0.07 27 ± 0.5 26 ± 0.1 26 ± 0.6 26 ± 0.1 25 ± 0.3 
Systolic blood 
pressure, 
mm/Hg 
118.26 ± 0.18 118.69 ± 1.12 137 ± 0.2 141 ± 2 143 ± 0.4 143 ± 2 123 ± 0.3 126 ± 1.8 NA NA 141 ± 0.3 141 ± 2 
Fasting 
glucose, mg/dl 103.69 ± 0.29 102.22 ± 1.52 104 ± 0.4 105 ± 2 NA NA 98 ± 0.5 99 ± 3 NA NA 93 ± 0.3 93 ± 2 
Active cigarette 
smoking, % 24 19 47 53 45 52 15 19 9 9 28 26 
Type 2 
diabetes, % 6 7 7 8 3 0 4 3 5 3 3 2 
ARIC, Atherosclerosis Risk in Communities Study; CCHS, Copenhagen City Heart Study; DCH, Danish Diet, Cancer, and Health Study; FHS, Framingham Heart Study; HPFS, Health 
Professionals Follow-up Study; MDCS, Malmö Diet and Cancer Study 
All continuous traits are given as means ± SEM. All categorical variables are shown in percentages.  
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Supplementary Table 6.  Association of LIPG Asn396Ser with Plasma Low-Density Lipoprotein  
Cholesterol or Triglycerides in Four Prospective Cohort Studies  
 N Beta SE P 
 Low-density lipoprotein cholesterol 
ARIC 8,588 0.024 0.019 0.21 
CCHS 9,618 0.006 0.021 0.77 
FHS 1,589 0.013 0.041 0.75 
MDCS-CC 5,045 0.031 0.089 0.73 
Meta-analysis 24,840 0.016 0.013 0.23 
 Triglycerides 
ARIC 8,720 -0.018 0.033 0.60 
CCHS 9,618 0.062 0.035 0.07 
FHS 1,589 -0.016 0.091 0.86 
MDCS-CC 5,175 0.001 0.088 0.99 
Meta-analysis 25,012 0.016 0.02 0.47 
The four prospective cohort studies were:  1) ARIC, Atherosclerosis Risk in Communities Study; 2) CCHS, 
Copenhagen City Heart Study; 3) FHS, Framingham Heart Study; and 4) MDCS-CC, Malmö Diet and Cancer 
Study-Cardiovascular Cohort 
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Supplementary Table 7.  Association of LIPG Asn396Ser with Cardiovascular Risk 
Factors in the Malmo Diet and Cancer Study.   
Risk factor N Beta SE P 
Systolic blood 
pressure 
27,868 -0.80 0.69 0.24 
Body mass index 27,863 -0.19 0.15 0.20 
Type 2 diabetes 2,452 cases, 23,326 
non-cases 
-0.05 0.13 0.70 
C-reactive protein 5,110 -0.55 0.40 0.17 
Small LDL particle 
concentration 
4,466 -0.07 0.09 0.47 
Linear regression modeling was utilized to test the association of LIPG Asn396Ser with systolic blood pressure, body mass index,  
C-reactive protein or small LDL particle concentration.  In these models, the predictor variable was the quantitative risk factor,  
the predictor variable was number of copies of the LIPG 396Ser allele, and covariates of age and gender.  For type 2 diabetes,  
logistic regression modeling was utilized.  
*Small LDL particle concentration measured by airborne ion mobility assay. 
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Supplementary Table 8.  Association of LIPG Asn396Ser with a range of cardiovascular 
phenotypes in the Atherosclerosis Risk in Communities (ARIC) Study 
Phenotype Beta SE N P 
HDL cholesterol 5.41 1.01 8,720 9.6 x 10-8 
apo-AI 8.63 1.93 8,720 7.9 x 10-6 
LDL cholesterol 2.98 2.53 8,588 0.24 
apoB 1.00 1.86 8,719 0.59 
Lp(a) -4.18 6.27 8,576 0.50 
Log triglycerides -0.02 0.03 8,720 0.53 
Systolic blood pressure 0.28 1.09 8,734 0.26 
Diastolic blood pressure 0.75 0.66 8,734 0.26 
Fasting glucose -1.57 1.78 8,731 0.38 
Type 2 diabetes 0.003 0.02 8,731 0.89 
Cigarette smoking -0.055 0.03 8,731 0.06 
Waist/hip ratio -0.0003 0.005 8,727 0.95 
Fibrinogen 0.91 4.06 8,704 0.82 
Log C-reactive protein -0.05 0.08 7,032 0.51 
Genotypes were coded as Serine allele carrier or non-carrier.  Linear or logistic regression was 
performed with outcome variable being phenotype in column 1, predictor variable of Serine allele 
carrier status, and covariates of age and gender.  Betas are unstandardized and in original units for 
phenotype except for triglycerides and C-reactive protein where these phenotypes were log-
transformed. 
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Supplementary Table 9.  Evaluation of an LDL genetic score for association with myocardial infarction  
   Data from Global Lipid Genetic 
Consortium GWAS for Lipids 
Data from CARDIOGRAM  
GWAS for MI 
Marker Effect Allele 
Other 
Allele Effect* SD P Effect SD P 
rs11136341 G A 0.041 0.006 6.20E-11 -0.032 0.030 0.310 
rs11220462 A G 0.057 0.008 1.88E-14 0.040 0.029 0.555 
rs1169288 C A 0.042 0.005 2.21E-14 0.084 0.019 7.55E-05 
rs12027135 T A 0.032 0.005 5.61E-10 -0.001 0.018 0.869 
rs12916 C T 0.072 0.005 2.46E-41 0.0238 0.019 0.225 
rs1800562 G A 0.065 0.011 1.39E-08 0.016 0.037 0.674 
rs217386 G A 0.034 0.005 2.86E-10 0.029 0.019 0.125 
rs2332328 T C 0.034 0.006 6.75E-10 0.001 0.027 0.933 
rs3757354 C T 0.042 0.006 2.34E-11 0.025 0.026 0.339 
rs514230 T A 0.033 0.005 5.99E-10 0.009 0.018 0.894 
rs649129 T C 0.060 0.006 1.03E-21 0.119 0.024 6.17E-05 
rs6511720 G T 0.206 0.009 1.03E-117 0.176 0.046 2.37E-04 
rs7225700 C T 0.026 0.005 1.53E-06 0.030 0.019 0.194 
The beta coefficient for association of LDL genetic score with MI was 0.756, SE of 0.119 and P= 1.8 x 10-10 
*Effect is in standard deviation units 
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Supplementary Table 10.  Evaluation of an HDL genetic score for association with myocardial infarction  
   Data from Global Lipid Genetic 
Consortium GWAS for Lipids 
Data from CARDIOGRAM  
GWAS for MI 
Marker Effect Allele 
Other 
Allele Effect* SD P Effect SD P 
rs13107325 C T 0.056 0.011 2.22E-07 0.004 0.053 0.912 
rs1689800 A G 0.031 0.005 1.43E-09 -0.020 0.019 0.334 
rs16942887 A G 0.085 0.007 8.62E-29 -0.038 0.028 0.125 
rs181362 C T 0.031 0.006 7.10E-07 -0.004 0.022 0.846 
rs2293889 G T 0.029 0.005 1.18E-08 0.038 0.018 0.040 
rs2923084 A G 0.027 0.006 3.21E-05 0.015 0.023 0.382 
rs386000 C G 0.055 0.007 2.92E-13 0.007 0.028 0.760 
rs4082919 T G 0.027 0.005 2.57E-07 0.005 0.019 0.667 
rs4759375 T C 0.057 0.011 6.30E-08 -0.013 0.038 0.548 
rs7134594 T C 0.030 0.005 1.26E-09 0.005 0.018 0.844 
rs7255436 A C 0.030 0.005 2.70E-08 -0.024 0.022 0.322 
rs737337 T C 0.043 0.009 3.48E-06 -0.036 0.035 0.358 
rs838880 C T 0.040 0.006 1.18E-11 0.008 0.023 0.825 
rs881844 G C 0.034 0.005 2.87E-11 0.001 0.019 0.772 
The beta coefficient for association of HDL genetic score with MI was -0.077, SE of 0.159 and P= 0.63 
*Effect is in standard deviation units 
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